Mesoblast Limited (AU:MSB) has released an update.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top Wall Street ...

More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.

These shares are ending the week positively. But why? The post Why Bowen Coal, Droneshield, Mesoblast, and St Barbara shares ...

Mesoblast announces that the FDA approved Ryoncil. Ryoncil is the only approved therapy for steroid-refractory acute graft ...

Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating ...

Mesoblast (NASDAQ:MESO – Get Free Report) was downgraded by investment analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research report issued on Monday, MarketBeat ...

Jefferies downgraded Mesoblast (MESO) to Hold from Buy with a price target of A$2.30, up from A$1.10. The firm updated the company’s for the ...

The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that ...

Investors are sending the Mesoblast share price tumbling on Friday. But why? The post Why the Mesoblast share price is diving ...

FDA approval for Mesoblast’s cell therapy used to treat children for complications that can occur during bone marrow ...

Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the U.S. Ryoncil is the only MSC therapy ...

Mesoblast shareholders are sitting on as much as 10-fold gains for the year, after the US Food and Drug Administration ...